These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19249806)

  • 1. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.
    Burke B; Gómez-Román VR; Lian Y; Sun Y; Kan E; Ulmer J; Srivastava IK; Barnett SW
    Virology; 2009 Apr; 387(1):147-56. PubMed ID: 19249806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
    Lian Y; Srivastava I; Gómez-Román VR; Zur Megede J; Sun Y; Kan E; Hilt S; Engelbrecht S; Himathongkham S; Luciw PA; Otten G; Ulmer JB; Donnelly JJ; Rabussay D; Montefiori D; van Rensburg EJ; Barnett SW
    J Virol; 2005 Nov; 79(21):13338-49. PubMed ID: 16227256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.
    Barnett SW; Burke B; Sun Y; Kan E; Legg H; Lian Y; Bost K; Zhou F; Goodsell A; Zur Megede J; Polo J; Donnelly J; Ulmer J; Otten GR; Miller CJ; Vajdy M; Srivastava IK
    J Virol; 2010 Jun; 84(12):5975-85. PubMed ID: 20392857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
    Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
    Front Immunol; 2020; 11():984. PubMed ID: 32582155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.
    Joachim A; Bauer A; Joseph S; Geldmacher C; Munseri PJ; Aboud S; Missanga M; Mann P; Wahren B; Ferrari G; Polonis VR; Robb ML; Weber J; Tatoud R; Maboko L; Hoelscher M; Lyamuya EF; Biberfeld G; Sandström E; Kroidl A; Bakari M; Nilsson C; McCormack S
    PLoS One; 2016; 11(5):e0155702. PubMed ID: 27192151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.
    Lai RP; Seaman MS; Tonks P; Wegmann F; Seilly DJ; Frost SD; LaBranche CC; Montefiori DC; Dey AK; Srivastava IK; Sattentau Q; Barnett SW; Heeney JL
    PLoS One; 2012; 7(4):e35083. PubMed ID: 22509385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
    Spearman P; Lally MA; Elizaga M; Montefiori D; Tomaras GD; McElrath MJ; Hural J; De Rosa SC; Sato A; Huang Y; Frey SE; Sato P; Donnelly J; Barnett S; Corey LJ;
    J Infect Dis; 2011 Apr; 203(8):1165-73. PubMed ID: 21451004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.
    Gach JS; Mara KJV; LaBranche CC; van Gils MJ; McCoy LE; Klasse PJ; Montefiori DC; Sanders RW; Moore JP; Forthal DN
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31375582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies.
    Chege GK; Burgers WA; Müller TL; Gray CM; Shephard EG; Barnett SW; Ferrari G; Montefiori D; Williamson C; Williamson AL
    Vaccine; 2017 Feb; 35(6):929-937. PubMed ID: 28069361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.
    Dey AK; Burke B; Sun Y; Hartog K; Heeney JL; Montefiori D; Srivastava IK; Barnett SW
    Vaccine; 2012 Apr; 30(17):2749-59. PubMed ID: 22366638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.
    Malherbe DC; Pissani F; Sather DN; Guo B; Pandey S; Sutton WF; Stuart AB; Robins H; Park B; Krebs SJ; Schuman JT; Kalams S; Hessell AJ; Haigwood NL
    J Virol; 2014 Nov; 88(22):12949-67. PubMed ID: 25210191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
    Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.